Vaccines for prevention of human papillomavirus infection.

https://arctichealth.org/en/permalink/ahliterature170202
Source
Issues Emerg Health Technol. 2005 Dec;(75):1-4
Publication Type
Article
Date
Dec-2005
Author
V. Foerster
J. Murtagh
Source
Issues Emerg Health Technol. 2005 Dec;(75):1-4
Date
Dec-2005
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Canada
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Female
Humans
Immunization Schedule
Papillomaviridae - immunology
Papillomavirus Infections - complications - epidemiology - prevention & control
Papillomavirus Vaccines
Uterine Cervical Neoplasms - epidemiology - etiology - prevention & control
Viral Vaccines - administration & dosage
Abstract
(1) High risk types of human papillomavirus (HPV) are the causal agents of cervical cancer. The prevention of HPV infection can reduce the incidence of this cancer. (2) Five phase II clinical trials have been published, and several large phase III trials are underway. (3) Trials have shown marked reductions in HPV infection. Most studies did not evaluate the effect of the vaccines on cancer because of lengthy time spans between HPV infection and the development of cancer. (4) Injection site pain, headache, and fatigue are the most common adverse events reported. (5) Important considerations include vaccine efficacy; acceptability; integration into existing vaccine schedules; cost; role of cervical screening programs; and access, particularly for people in the developing world.
PubMed ID
16544439 View in PubMed
Less detail